Amylyx Pharmaceuticals, Inc.
AMLX
株式のランク
#4619
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
株価
$26.73
時価総額
$3.36B
変化（1日）
1.49%
変化（1年）
78.81%
国
US
取引 Amylyx Pharmaceuticals, Inc. (AMLX)
カテゴリー
Healthcare
Amylyx Pharmaceuticals, Inc.（AMLX）のEPS
June 2026 時点のEPS TTM: $-1.41
Amylyx Pharmaceuticals, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-1.41です。2023年末には、EPSは$0.73で、2022年のEPS$-2.98と増加でした。
Amylyx Pharmaceuticals, Inc.のEPS履歴（2019から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
